Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :

EU HIV/AIDS Civil Society Forum: We call on your leadership

Civil society organisations are calling for renewed political leadership at European level that is based on evidence based policy, not ideology.

More information in the attached press release:

EU HIVAIDS Civil Society Forum - We call on your leadership.pdf (0.40) MB
EU HIVAIDS Civil Society Forum - We call on your leadership, Russian.pdf (0.12) MB

ECDC: Pre-exposure prophylaxis for HIV in Europe

The use of pre-exposure prophylaxis (PrEP) as an HIV prevention strategy, particularly among men who have sex with men (MSM) as well as other population groups at higher risk of HIV infection, has been receiving more and more attention during 2014. Preliminary results of clinical trials and research studies suggest that it could be an effective HIV prevention tool for Europe. As...


Source Source: ECDC

VAX November 2014

VAX is a bulletin on AIDS vaccine research and news intended for a broad audience, ranging from policymakers and community leaders to advocates and vaccine trial volunteers. Each issue features a collection of articles written in an easily-accessible style allowing non-technical readers to understand the latest developments in the science and policy of AIDS vaccine research....


Source Source: VAX Report

Pakistan: Sovaldi – ‘miracle’ hepatitis C oral drug gets official nod

LAHORE: The Drug Regulatory Authority of Pakistan (DRAP) has finally fixed price of the ‘blockbuster’ oral drug - Sovaldi – after its registration in Pakistan, giving a good news to hepatitis C patients. The decision was taken in a meeting of DRAP’s Drug Price Committee presided over by Pricing Director Mr Amanullah in Islamabad on Thursday, a senior official...


Source Source: Dawn

AASLD 2014: AbbVie 3D cures recurrent HCV in most liver transplant recipients without cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis or cirrhosis, according to results from the CORAL-I study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this...